By Canon, Inc.
LAKE SUCCESS, N.Y., November 16, 2010 – Canon U.S.A., Inc., a leader in digital imaging, today announced the Canon CR-2 Digital Non-Mydriatic Retinal Camera has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)1.
Integrating the latest in Canon's retinal imaging technology and enhancements in a compact frame, the Canon CR-2 Digital Non-Mydriatic Retinal Camera is the Company's newest and lightest retinal camera to date, weighing only 33 pounds. The CR-2 retinal camera can be easily installed or for added convenience, can be easily transported when needed. The illuminated control panel allows medical staff to easily navigate operations in darkened rooms. Contributing to a lower total-cost-of-ownership, the white LED lamp used in the CR-2 retinal camera uses less power than a xenon tube and lasts approximately twice as long, which can help to reduce energy costs in medical facilities.
"Obtaining FDA clearance of the CR-2 Digital Non-Mydriatic Retinal Camera helps reaffirm our commitment to eye care professionals by instituting superb imaging technology and in turn, contributing to the quality care of their patients." said Tsuneo Imai, senior director and general manager, Medical Systems Division, Canon U.S.A.
The CR-2 Digital Non-Mydriatic Retinal Camera joins Canon's complete line of total digital imaging solutions and workflow management solutions for ophthalmic professionals. The CR-2 retinal camera is available for purchase through authorized Canon dealers.
Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions. Its parent company, Canon Inc. (NYSE:CAJ), a top patent holder of technology, ranked fourth overall in the U.S. in 2009†, with global revenues of US $35 billion, is listed as number six in the computer industry on Fortune Magazine's World's Most Admired Companies 2010 list, and is on the 2009 BusinessWeek list of "100 Best Global Brands." Canon U.S.A. is committed to the highest levels of customer satisfaction and loyalty, providing 100 percent U.S.-based consumer service and support for all of the products it distributes. At Canon, we care because caring is essential to living together in harmony. Founded upon a corporate philosophy of Kyosei – "all people, regardless of race, religion or culture, harmoniously living and working together into the future" – Canon U.S.A. supports a number of social, youth, educational and other programs, including environmental and recycling initiatives.
Sunday, November 28, 2010
Monday, November 22, 2010
Ophthalmologists Experience Visual Maladies To Improve Care for Patients
by Dave McKinley & Dooley O'Rourke
BUFFALO, NY - It is said one can learn much by walking a mile in another person's shoes.
Such was the case Thursday night at the Olmsted Center for Sight on Main Street, where a unique exercise was held to help physicians provide better care for their patients.
"Well we came up with this crazy idea actually," said the center's Director of Marketing Linda Wiecek, in describing how two dozen area Ophthalmologists were invited to sit down for dinner, in a fashion which would allow them to share their patients' view of the world --or lack thereof.
Upon their arrival each doctor was asked to choose a festive mardi gras style mask to wear at the event.
However, the eye holes of each mask were outfitted with occluders, to simulate one of the four most common causes of visual impairments.
Upon donning a mask to simulate macular degeneration, Dr. Paul Lee suddenly found that the middle of his field of vision had been impaired.
"Macular degeneration is the leading cause of vision loss in the country, and often times its irreversible so the earlier you diagnose it the better we can treat you," Dr. Lee told WGRZ-TV.
In contrast, Dr. Melissa Neal selected a mask outfitted to simulate the effects of glaucoma, and set about discovering what it was like for a person with impaired peripheral vision.
"In my former practice, I treated a lot of patients with glaucoma and I kind of have a passion for it," she explained
After socializing, and struggling a bit with their new found disabilities, the doctors sat down for dinner...then the lights were turned out.
They proceeded to dine as many of their patients do -- in the dark.
Some gingerly set about consuming their meals, at times struggling to find their drinking glasses or silverware and put fork-to plate-to mouth.
The whole idea of temporarily disabling their sight was to make them better doctors by seeing through the eyes of their patients.
"It's tougher than I thought," said Dr. Lee. "I kept on bumping into my colleagues ...it's a whole lot different than I really thought it was going to be."
"I'll never truly understand (living with glaucoma) because when things got more difficult I could just take my mask off," Said Dr. Neal. "But it does give me a little bit more sympathy and understanding for my patients and their frustrations," she said.
BUFFALO, NY - It is said one can learn much by walking a mile in another person's shoes.
Such was the case Thursday night at the Olmsted Center for Sight on Main Street, where a unique exercise was held to help physicians provide better care for their patients.
"Well we came up with this crazy idea actually," said the center's Director of Marketing Linda Wiecek, in describing how two dozen area Ophthalmologists were invited to sit down for dinner, in a fashion which would allow them to share their patients' view of the world --or lack thereof.
Upon their arrival each doctor was asked to choose a festive mardi gras style mask to wear at the event.
However, the eye holes of each mask were outfitted with occluders, to simulate one of the four most common causes of visual impairments.
Upon donning a mask to simulate macular degeneration, Dr. Paul Lee suddenly found that the middle of his field of vision had been impaired.
"Macular degeneration is the leading cause of vision loss in the country, and often times its irreversible so the earlier you diagnose it the better we can treat you," Dr. Lee told WGRZ-TV.
In contrast, Dr. Melissa Neal selected a mask outfitted to simulate the effects of glaucoma, and set about discovering what it was like for a person with impaired peripheral vision.
"In my former practice, I treated a lot of patients with glaucoma and I kind of have a passion for it," she explained
After socializing, and struggling a bit with their new found disabilities, the doctors sat down for dinner...then the lights were turned out.
They proceeded to dine as many of their patients do -- in the dark.
Some gingerly set about consuming their meals, at times struggling to find their drinking glasses or silverware and put fork-to plate-to mouth.
The whole idea of temporarily disabling their sight was to make them better doctors by seeing through the eyes of their patients.
"It's tougher than I thought," said Dr. Lee. "I kept on bumping into my colleagues ...it's a whole lot different than I really thought it was going to be."
"I'll never truly understand (living with glaucoma) because when things got more difficult I could just take my mask off," Said Dr. Neal. "But it does give me a little bit more sympathy and understanding for my patients and their frustrations," she said.
Tuesday, November 16, 2010
Calvert Research Awarded $245,000 to support futher Development of its Age-Related Macular Degeneration Drug Candidate
By Calvert Research
Calvert Research, LLC announced today that one of the Company’s therapeutic development programs (T1-1081) qualified to receive federal grant funding totaling approximately $245,000 under the Patient Protection and Affordable Care Act of 2010 (“The ACT”), which will be used to help advance T1-1081 toward an IND application filing.
The Act created a $1.0 billion federal program to provide grants or tax credits to help support certain “Qualifying Therapeutic Discovery Projects” that have been designated by the Department of Health and Human Services using the following criteria: (a) the potential to create a novel therapy to treat unmet medical needs; (b) the potential to reduce long-term health care costs in the U.S., and (c) be among those projects with the greatest potential to create and sustain jobs and increase U.S. competitiveness.
T1-1081 is currently undergoing preclinical evaluation as a potentially more effective treatment for the wet form of Age-related Macular Degeneration (AMD), which is a major cause of significant vision loss in people over age 50 affecting millions worldwide. T1-1081 was specifically designed to affect multiple factors that lead to vision loss by targeting and destroying unwanted blood vessels in the back of the eye that cause this disease, by blocking formation of new blood vessels, and by reducing inflammation that damages retinal cells. T1-1081 also has the potential to treat other serious ocular diseases such as diabetic retinopathy, and the dry form of AMD
“We are very pleased to have been awarded the maximum amount from this competitive grant program, which will be used to help advance T1-1081 toward human clinical studies,” said Dr. Michael A. Recny, President of Calvert Research. “We licensed rights to develop and commercialize T1-1081 from Tulane University in 2009, and it represents a key component of our strategy to assemble a diverse portfolio of novel preclinical stage therapeutic compounds that we can advance quickly and efficiently toward human studies by leveraging our extensive in-house preclinical development expertise together with our preferred network of contract service partners”.
About Calvert Research
Commercial success in building the next generation of therapeutic drugs begins with identifying and acquiring the rights to the best potential drug candidates from top academic institutions and early stage biotechnology companies. Calvert Research has long-established relationships with the leaders in over 160 academic technology transfer departments across North America and thousands of researchers at these institutions to source the best opportunities for investment.
Calvert Research designs a customized, integrated approach for each new drug candidate it acquired by utilizing senior scientists who have world-class experience in the design and submission of IND enabling preclinical development studies to regulatory agencies worldwide. Since 2004, Calvert Research has invested in four preclinical stage therapeutic development programs, and to date has achieved three successful exits from selling or sublicensing rights to commercial partners, demonstrating a proven track record of success.
About Calvert Holdings, Inc.
Formed in 1996, Calvert Holdings, Inc. (http://www.calvertholdings.com) is a privately-held company consisting of a diverse portfolio of companies including Calvert Labs, Calvert Research, Calvert Corporate Funding, and Calvert Creative.
Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.
About Calvert Labs
As a global service provider, Calvert Labs' core offerings include toxicology (acute through chronic & carcinogenicity plus reproductive and developmental), pharmacokinetics & ADME, pharmacology, safety pharmacology, immunotoxicology and immunology.
About Calvert Corporate Funding
Calvert Corporate Funding has emerged from its parent, Calvert Holdings, Inc., to address the needs of small and mid-sized companies seeking an alternative source of capital from traditional banking and lending institutions. Recent economic challenges, financial reform, and bank credit restrictions have created a need for viable options to be made available to business owners and operators.
In addition to its extensive network of non-bank lenders, Calvert Corporate Funding is a direct representative of the Global Finance Group, whose network includes a consortium of seventeen non-bank lenders. This array of investors specializes in lending to credit-worthy business owners/operators using creative financial packages. Due to our extensive banking and asset-based lending experience, we are able to identify the optimum lender/company match.
Calvert Research, LLC announced today that one of the Company’s therapeutic development programs (T1-1081) qualified to receive federal grant funding totaling approximately $245,000 under the Patient Protection and Affordable Care Act of 2010 (“The ACT”), which will be used to help advance T1-1081 toward an IND application filing.
The Act created a $1.0 billion federal program to provide grants or tax credits to help support certain “Qualifying Therapeutic Discovery Projects” that have been designated by the Department of Health and Human Services using the following criteria: (a) the potential to create a novel therapy to treat unmet medical needs; (b) the potential to reduce long-term health care costs in the U.S., and (c) be among those projects with the greatest potential to create and sustain jobs and increase U.S. competitiveness.
T1-1081 is currently undergoing preclinical evaluation as a potentially more effective treatment for the wet form of Age-related Macular Degeneration (AMD), which is a major cause of significant vision loss in people over age 50 affecting millions worldwide. T1-1081 was specifically designed to affect multiple factors that lead to vision loss by targeting and destroying unwanted blood vessels in the back of the eye that cause this disease, by blocking formation of new blood vessels, and by reducing inflammation that damages retinal cells. T1-1081 also has the potential to treat other serious ocular diseases such as diabetic retinopathy, and the dry form of AMD
“We are very pleased to have been awarded the maximum amount from this competitive grant program, which will be used to help advance T1-1081 toward human clinical studies,” said Dr. Michael A. Recny, President of Calvert Research. “We licensed rights to develop and commercialize T1-1081 from Tulane University in 2009, and it represents a key component of our strategy to assemble a diverse portfolio of novel preclinical stage therapeutic compounds that we can advance quickly and efficiently toward human studies by leveraging our extensive in-house preclinical development expertise together with our preferred network of contract service partners”.
About Calvert Research
Commercial success in building the next generation of therapeutic drugs begins with identifying and acquiring the rights to the best potential drug candidates from top academic institutions and early stage biotechnology companies. Calvert Research has long-established relationships with the leaders in over 160 academic technology transfer departments across North America and thousands of researchers at these institutions to source the best opportunities for investment.
Calvert Research designs a customized, integrated approach for each new drug candidate it acquired by utilizing senior scientists who have world-class experience in the design and submission of IND enabling preclinical development studies to regulatory agencies worldwide. Since 2004, Calvert Research has invested in four preclinical stage therapeutic development programs, and to date has achieved three successful exits from selling or sublicensing rights to commercial partners, demonstrating a proven track record of success.
About Calvert Holdings, Inc.
Formed in 1996, Calvert Holdings, Inc. (http://www.calvertholdings.com) is a privately-held company consisting of a diverse portfolio of companies including Calvert Labs, Calvert Research, Calvert Corporate Funding, and Calvert Creative.
Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.
About Calvert Labs
As a global service provider, Calvert Labs' core offerings include toxicology (acute through chronic & carcinogenicity plus reproductive and developmental), pharmacokinetics & ADME, pharmacology, safety pharmacology, immunotoxicology and immunology.
About Calvert Corporate Funding
Calvert Corporate Funding has emerged from its parent, Calvert Holdings, Inc., to address the needs of small and mid-sized companies seeking an alternative source of capital from traditional banking and lending institutions. Recent economic challenges, financial reform, and bank credit restrictions have created a need for viable options to be made available to business owners and operators.
In addition to its extensive network of non-bank lenders, Calvert Corporate Funding is a direct representative of the Global Finance Group, whose network includes a consortium of seventeen non-bank lenders. This array of investors specializes in lending to credit-worthy business owners/operators using creative financial packages. Due to our extensive banking and asset-based lending experience, we are able to identify the optimum lender/company match.
Subscribe to:
Comments (Atom)
